PUBLISHER: IMARC | PRODUCT CODE: 1451790
PUBLISHER: IMARC | PRODUCT CODE: 1451790
The global reproductive genetics market size reached US$ 5.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 50.1 Billion by 2032, exhibiting a growth rate (CAGR) of 26.5% during 2024-2032. The growing awareness and understanding of genetic disorders among the masses, the rising adoption of preventive healthcare, and the increasing fertility rates leading to a higher uptake of assisted reproductive technologies (ART) represent some of the key factors driving the market.
Reproductive genetics refers to the branch of genetics that focuses on the study of genetic information and its impact on reproductive health and outcomes. It involves the analysis and understanding of genetic factors related to fertility, pregnancy, and the transmission of genetic disorders from parents to their offspring. Reproductive genetics encompasses various techniques and technologies aimed at identifying and managing genetic conditions during the reproductive process. Screening individuals or couples for specific genetic mutations or carrier status to assess the risk of passing on genetic disorders to their children. In assisted reproductive technologies such as in vitro fertilization (IVF), PGD involves the analysis of embryos for genetic abnormalities before their implantation in the uterus, helping to select embryos without specific genetic disorders. Reproductive genetics helps assess the risk of transmitting genetic disorders to offspring by identifying carrier status or the presence of specific genetic mutations in individuals or couples.
The global market is primarily driven by the growing awareness and understanding of genetic disorders among the masses. Also, the rising adoption of preventive healthcare leading to a higher number of prospective parents undergoing genetic testing to understand the risks of genetic disorders in their future children is fueling the market. With the increasing fertility rates, there is a higher uptake of assisted reproductive technologies (ART) such as In-Vitro Fertilization (IVF) and surrogacy, which is creating a positive market outlook. In line with this, continual technological developments in advanced genetic testing techniques such as Next-Generation Sequencing (NGS) and high-resolution microarrays are stimulating the market. Moreover, the increasing maternal age resulting in a higher susceptibility of chromosomal abnormalities in women is providing an impetus to the market. In addition to this, governments of several countries are increasingly supporting genetic research and testing, thereby catalyzing the growth of the market. The market is further driven by the rising affordability of genomic sequencing procedures, resulting in higher accessibility among the masses. Some of the other factors contributing to the market include inflating income levels, particularly in developing countries, the proliferation of organizations offering direct-to-consumer genetic tests, continual innovations in personalized medicine, and extensive research and development (R&D) activities.
IMARC Group provides an analysis of the key trends in each segment of the global reproductive genetics market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product type, procedure type, technology and application.
Kits
Laboratory Developed Tests (LDT)
Reagents and Consumables
The report has provided a detailed breakup and analysis of the reproductive genetics market based on the product type. This includes kits, laboratory developed tests (LDT), and reagents and consumables. According to the report, kits represented the largest segment.
Carrier Screening
Pre-Natal Screening
Pre-Implantation Genetic Testing
Infertility Genetic Testing
A detailed breakup and analysis of the reproductive genetics market based on the procedure type has also been provided in the report. This includes carrier screening, pre-natal screening, pre-implantation genetic testing, and infertility genetic testing. According to the report, carrier screening accounted for the largest market share.
Next-Generation Sequencing
Polymerase Chain Reaction
In Situ Hybridization (ISH/FISH)
Microarray
The report has provided a detailed breakup and analysis of the reproductive genetics market based on the technology. This includes next-generation sequencing, polymerase chain reaction, in situ hybridization (ISH/FISH), and microarray. According to the report, next-generation sequencing represented the largest segment.
Aneuploidy
Structural Chromosomal Abnormality
Single Gene Disorder
Others
A detailed breakup and analysis of the reproductive genetics market based on the application has also been provided in the report. This includes aneuploidy, structural chromosomal abnormality, single gene disorder, and others. According to the report, aneuploidy accounted for the largest market share.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for reproductive genetics. Some of the factors driving the North America reproductive genetics market included its continual technological advancements in the field of genetics, the rising adoption of preventive healthcare high healthcare expenditure, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global reproductive genetics market. Detailed profiles of all major companies have been provided. Some of the companies covered include Bangkok Genomics Innovation Public Company Limited, Centogene N.V., Fulgent Genetics Inc., Igenomix (Vitrolife Group), Invitae Corporation, Laboratory Corporation of America Holdings, PerkinElmer Inc., Thermo Fisher Scientific Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.